Skip to main content

Table 1 Inclusion and exclusion criteria

From: A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study

Inclusion criteria Exclusion criteria
 - Patients aged 18 to 85 years
 - First HER2 positive breast cancer, confirmed histologically
 - WHO Performance status ≤1
 - Completed chemo-radiotherapy
 - Normal renal function (creatinine clearance ≥60 ml.min-1)
 - Normal heart function with LVEF ≥50% (As assessed by echocardiography dating from less than 3 months previously)
 - Normal liver function (normal ASAT and ALAT)
 - Certificate of non-contraindication to the practice of physical activity
 - Active contraception or menopaused
- HER2 negative Breast cancer
- Patients with metastases
- Heart failure (LVEF ≤50%)
- Resting oxygen saturation (SaO2) ≤ 92%
- Autoimmune disease (systemic lupus erythematosus, rheumatoid arthritis)
- Symptomatic osteoarthritis, cardiovascular disease (angina or uncontrolled hypertension) or lung disease (chronic obstructive pulmonary disease)
- Patients suffering from malnutrition (body mass index <18 kg.m−2) or weight loss of >10% during the previous 3 months
- Patients with psychiatric or cognitive disorders deemed unsuitable for physical activity
- Pregnant or breastfeeding patients